Corresponding author:
Flora T Musuamba
Belgian Federal Agency for Medicines and Health Products, B-1060 Brussels, Belgium
flora.musuambashinanu@afmps.be
Principal Investigator statement: The authors confirm that there is no principal investigator in this study because this study only includes observational data from standard clinical practice data.
Conflict of interest: The authors declared no competing interest for this work.
Data availability statement : The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Word count: Abstract: 250/ Text: 2988
Table count : 3
Figure count : 3
Keywords: Hydroxychloroquine, modelling and simulations, dosing rationale, dosing optimization, pharmacokinetics
Running title: Hydroxychloroquine dosing in COVID-19 patients